Clinical trial NCT05211570 - References

Acute Myeloid Leukemia, in Relapse — AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Citation(s)

•   Goubard A, Humbert M, Mansfield C, Hermine O, Dubreuil P, et al
  AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, is Active Across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes. Blood (2019) 134 (Supplement_1): 5154. doi.org/10.1182/blood-2019-127021
•   Goubard A, Humbert M, Mansfield C, Hermine O, Dubreuil P, et al
  In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-derived Xenograft Models of Acute Myeloid Leukemia. Blood (2019) 134 (Supplement_1): 5142. doi.org/10.1182/blood-2019-127143
•   Humbert M, Goubard A, Mansfield C, Hermine O, Dubreuil P, et al
  Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939. Blood (2019) 134 (Supplement_1): 2075. doi.org/10.1182/blood-2019-122540

A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Details for clinical trial NCT05211570